Inhibitors of Apoptotic Proteins: New Targets for Anticancer Therapy
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Inhibitors of apoptotic proteins (IAP s) can play an important role in inhibiting apoptosis by exerting their negative action on caspases (apoptotic proteins). There are eight proteins in this family: NAIP/BIRC 1/NLRB, cellular IAP 1 (cIAP 1)/human IAP 2/BIRC 2, cellular IAP 2 (cIAP 2)/human IAP 1/BIRC 3, X‐linked IAP (XIAP)/BIRC 4, survivin/BIRC 5, baculoviral IAP repeat (BIR)‐containing ubiquitin‐conjugating enzyme/apollon/BIRC 6, livin/melanoma‐IAP (ML‐IAP)/BIRC 7/KIAP, and testis‐specific IAP (T s‐IAP)/hILP‐2/BIRC 8. Deregulation of these inhibitors of apoptotic proteins (IAP s) may push cell toward cancer and neurodegenerative disorders. Inhibitors of apoptotic proteins (IAP s) may provide new target for anticancer therapy. Drugs may be developed that are inhibiting these IAP s to induce apoptosis in cancerous cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IAP proteins: blocking the road to death's door
Salvesen, G. S., & Duckett, C. S. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm830 · Cited by 1,756 · cited 2×
“There is 70- to 80-amino-acid-long motif in BIR domain that is related to their initial discovery in baculovirus, as indicated by the name (18).”
BackgroundHuman inhibitor of apoptosis proteins: why XIAP is the black sheep of the family
Eckelman, B. P., Salvesen, G. S., & Scott, F. L. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400795 · Cited by 813
The inhibitors of apoptosis (IAPs) as cancer targets
Hunter, A. M., LaCasse, E. C., & Korneluk, R. G. (2007) · Apoptosis · doi:10.1007/s10495-007-0087-3 · Cited by 565
Novel drugs from marine microorganisms
Javed, F., Qadir, M. I., Janbaz, K. H., & Ali, M. (2011) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2011.576234 · Cited by 72 · cited 2×
“This problem has been tried to be overcome by increasing the drug delivery to the target site by the use of polymers (1,2) or through nanotechnology (3,4), synthesis of new drugs, either by the use of proteomics (5), or synthesis from lactic acid bacteria (6), or marine micro-organisms (7).”
BackgroundSelf-citation
Cited by
Molecular Mechanisms of Apoptosis and Roles in Cancer Development and Treatment
Goldar, S., Khaniani, M. S., Derakhshan, S. M., & Baradaran, B. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.6.2129 · Cited by 606
Major apoptotic mechanisms and genes involved in apoptosis
Kiraz, Y., Adan, A., Kartal Yandim, M., & Baran, Y. (2016) · Tumor Biology · doi:10.1007/s13277-016-5035-9 · Cited by 582
Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies
Chen, X., Duan, N., Zhang, C., & Zhang, W. (2016) · Journal of Cancer · doi:10.7150/jca.13332 · Cited by 347
Small molecules targeting protein–protein interactions for cancer therapy
Wu, D., Li, Y., Zheng, L., Xiao, H., Ouyang, L., Wang, G., & Sun, Q. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.035 · Cited by 71
“6A), which includes two AVPI mimics with a linker that can target XIAP and interacts with the BIR3 domains of XIAP, c-IAP1, c-IAP2 and the single BIR domain of ML-IAP with K d values of 50, 1, 36, and 1 nmol/L, respectively.”
BackgroundStructures of BIRC6-client complexes provide a mechanism of SMAC-mediated release of caspases
Hunkeler, M., Jin, C. Y., & Fischer, E. S. (2023) · Science · doi:10.1126/science.ade5750 · Cited by 48
Metadata
- Authors
- Saleem, M., Qadir, M. I., Perveen, N., Ahmad, B., Saleem, U., Irshad, T., & Ahmad, B.
- Venue
- Chemical Biology & Drug Design
- Publisher
- Wiley
- Published
- 2013-08-22
- Volume
- 82
- Issue
- 3
- Pages
- 243-251
- ISSN
- 1747-0277 (ISSN-L)
- 1747-0285
- OpenAlex
- W2056654402
- Cited by
- 149
- References
- 4
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.